ZX008 0.2 or 0.8 mg/kg/day + Matching Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lennox Gastaut Syndrome
Conditions
Lennox Gastaut Syndrome
Trial Timeline
Nov 27, 2017 → May 23, 2024
NCT ID
NCT03355209About ZX008 0.2 or 0.8 mg/kg/day + Matching Placebo
ZX008 0.2 or 0.8 mg/kg/day + Matching Placebo is a phase 3 stage product being developed by UCB for Lennox Gastaut Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03355209. Target conditions include Lennox Gastaut Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03355209 | Phase 3 | Completed |
Competing Products
11 competing products in Lennox Gastaut Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + Perampanel | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Pre-clinical | 23 |
| Rufinamide (E2080) + Placebo | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Pre-clinical | 23 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Rufinamide + Any other approved Antiepileptic Drug | Eisai | Phase 3 | 77 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Pre-clinical | 20 |
| Cannabidiol | Jazz Pharmaceuticals | Approved | 82 |
| GWP42003-P | Jazz Pharmaceuticals | Approved | 82 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 72 |